Clinical trial
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia…
NCT00422591 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00422591 |
|---|---|
| Title | Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) |
| Official title | Prospective Evaluation of Standard Chemotherapy Regimen of Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Acute Myeloid Leukemia, AML |
| Intervention type | Drug |
| Interventions | Cytarabine, Idarubicin |
| Enrollment | 175 |
| Start date | Dec 1, 2006 |
| Primary completion | Jan 1, 2017 |
| Completion | Jan 1, 2017 |
| First posted | Jan 17, 2007 |
| Last update posted | Aug 23, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: